Utility of the Canadian treatment optimization recommendations (TOR) in MS care

Canadian Journal of Neurological Sciences

Volumn 40, Issue 4, 2013, Pages 527-535

  Grand'Maison, François ^a   Bhan, Virender ^b   Freedman, Mark S ^c   Myles, Mary L ^f   Patry, David G ^g   Selchen, Daniel H ^d   Moriarty, Patrick ^e   Traboulsee, Anthony L ^h  

^a HÔPITAL CHARLES LEMOYNE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e EMD Serono Canada Inc   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CANADA; CLINICAL MEDICINE; CONTROLLED STUDY; DEMYELINATING DISEASE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84879358106     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710001461X     Document Type: Article

References (14)

1. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4).: 655-61
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3).: 285-94 (Pubitemid 26100751)
3. PRISMS Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139).: 1498-504
4. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6).: 944-53 (Pubitemid 44454583)
5. Freedman M, Blumhardt L, Brochet B, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler. 2002;8(1).: 19-23 (Pubitemid 34193023)
6. Oger J, Freedman M. Consensus statement of the Canadian MS CLinics Network on: The use of disease modifying agents in multiple sclerosis. Can J Neurol Sci. 1999;26(4).: 274-5. (Pubitemid 29522811)
7. Bashir K, Buchwald L, Coyle P, et al. Optimizing immunomodulatory therapy for MS patients. Int J MS Care. 2002;4(2).: 3-7.
8. Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH. Treatment optimization in multiple sclerosis. Can J Neurol Sci. 2004;31(2).: 157-68 (Pubitemid 38724807)
9. Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR). as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: Analysis of the PRISMS study. Mult Scler. 2008;14(9).: 1234-41
10. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferonbeta- 1a in relapsing MS. Neurology. 2001;56(12).: 1628-36
11. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: Strategies for optimizing management. Neurologist. 2002;8(4).: 227-36 (Pubitemid 34810404)
12. Ruiz-Pena JL, Duque P, Izquierdo G. Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria. BMC Neurol. 2008;8: 3.
13. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study).: A multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7 (10).: 903-14
14. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsingremitting multiple sclerosis: A prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10).: 889-97